多替阿巴拉米片推荐的用量是多少？

It is a film-coated tablet that appears white or off-white after removing the coating. It is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). In January 2018, ViiV Healthcare, a joint venture of the British multinational pharmaceutical company GlaxoSmithKline (GSK), officially launched the innovative AIDS treatment drug Dolutegra (Inbec) in the Chinese market. 

Dolutegravir tablets are the only three-in-one compound drug containing dolutegravir (DTG), which integrates treatment drugs for different stages of viral infection in the same tablet. Patients only need to take one drug to achieve the effect of combined medication. The drug has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line first-line treatment for patients with HIV infection.

Existing research shows that one year (48 weeks) after HIV-infected patients were treated with dolutegravir tablets, 93% of the infected people's viral load became negative. Dolutegra is not suitable for individuals who carry the HLA-B5701 gene. Patients who carry this gene are at high risk of developing severe hypersensitivity reactions (type I allergic reactions) when using dolutea. Therefore, it is necessary to complete the test before taking Dolutea Paramid Tablets to determine whether you carry the special type of "HLA-B5701" gene. 

Common side effects of dolutegra tablets include nausea (12%), insomnia (7%), dizziness (6%) and headache (6%). Patients with abacavir hypersensitivity often experience nausea, vomiting, diarrhea, fever, drowsiness, rash and other symptoms when using this product. If patients experience these symptoms, they should be carefully evaluated for the presence of such a hypersensitivity reaction. Very rarely, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis may occur, and abacavir hypersensitivity cannot be excluded. For adults and adolescents, the recommended dose of Dolutegra is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given dolutea as dolutea is a fixed-dose tablet and cannot be reduced. Dolutegravir is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines.

The above is the content of the dosage, I hope it can help you!